Revlimid® (lenalidomide) – New warning
September 15, 2017 – The FDA approved an update to the Warnings and Precautions section of the Revlimid (lenalidomide) drug label regarding early mortality in patients with mantle cell lymphoma (MCL).
Download PDF
